Hemostemix (CVE:HEM) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Hemostemix Inc. (CVE:HEM)’s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$0.21 and traded as low as C$0.10. Hemostemix shares last traded at C$0.11, with a volume of 196,551 shares traded.

Hemostemix Trading Down 5.3 %

The firm’s 50-day moving average price is C$0.20 and its 200 day moving average price is C$0.13. The company has a market cap of C$13.12 million, a price-to-earnings ratio of -2.62 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.

Insider Buying and Selling

In other news, Director Peter Alan Lacey bought 200,000 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. 10.43% of the stock is owned by insiders.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.